Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22.042
Filter
1.
Science ; 385(6716): eadm7966, 2024 Sep 27.
Article in English | MEDLINE | ID: mdl-39325875

ABSTRACT

We report the discovery of MED6-189, an analog of the kalihinol family of isocyanoterpene natural products that is effective against drug-sensitive and drug-resistant Plasmodium falciparum strains, blocking both asexual replication and sexual differentiation. In vivo studies using a humanized mouse model of malaria confirm strong efficacy of the compound in animals with no apparent hemolytic activity or toxicity. Complementary chemical, molecular, and genomics analyses revealed that MED6-189 targets the parasite apicoplast and acts by inhibiting lipid biogenesis and cellular trafficking. Genetic analyses revealed that a mutation in PfSec13, which encodes a component of the parasite secretory machinery, reduced susceptibility to the drug. Its high potency, excellent therapeutic profile, and distinctive mode of action make MED6-189 an excellent addition to the antimalarial drug pipeline.


Subject(s)
Antimalarials , Apicoplasts , Diterpenes , Malaria, Falciparum , Plasmodium falciparum , Animals , Humans , Mice , Antimalarials/chemistry , Antimalarials/pharmacology , Apicoplasts/drug effects , Apicoplasts/metabolism , Disease Models, Animal , Drug Resistance/genetics , Malaria, Falciparum/drug therapy , Malaria, Falciparum/parasitology , Mutation , Plasmodium falciparum/drug effects , Plasmodium falciparum/genetics , Protozoan Proteins/metabolism , Protozoan Proteins/genetics , Diterpenes/chemistry , Diterpenes/pharmacology
2.
Malar J ; 23(1): 291, 2024 Sep 28.
Article in English | MEDLINE | ID: mdl-39342297

ABSTRACT

BACKGROUND: Malaria continues to cause unacceptably high levels of disease and death despite increased global efforts and is still significant public health problem. African countries are disproportionately affected by malaria. The objective of this study was to describe a rare case of haemorrhagic stroke as a possible complication of malaria in a 26-year-old male patient. CASE PRESENTATION: A 26-year-old male from southwest Ethiopia presented with complaint of loss of consciousness (LOC) of 12 h duration. He had fever, headache, vomiting, chills, rigors and shivering three days prior to the loss of consciousness. On physical examination, pulse rate 116 beats/min, blood pressure of 120/90 mmHg, respiratory rate was 24 breaths/min, a temperature of 38.9◦C and oxygen saturation of 94%. Nervous system examination; stuporous with Glasgow Coma Scale (GCS) 10/15(M5, E3, V2). Blood film and RDT confirmed a Plasmodium falciparum infection and a non-contrast CT scan found a right cerebral parenchymal haemorrhage. DISCUSSION AND CONCLUSION: The presented case described a very rare case of a 26-year-old male patient who was diagnosed with left side hemiparesis secondary to a haemorrhagic stroke, associated with P. falciparum malaria. This report highlights the fact that malaria with stroke should be considered a differential diagnosis in a patient presenting with body weakness in a malaria endemic area and in individuals who had travel history to malaria endemic areas.


Subject(s)
Hemorrhagic Stroke , Malaria, Falciparum , Humans , Male , Adult , Malaria, Falciparum/complications , Malaria, Falciparum/diagnosis , Hemorrhagic Stroke/etiology , Hemorrhagic Stroke/diagnosis , Ethiopia , Tomography, X-Ray Computed
3.
Nat Commun ; 15(1): 8285, 2024 Sep 27.
Article in English | MEDLINE | ID: mdl-39333562

ABSTRACT

Importation of malaria infections is a suspected driver of sustained malaria prevalence on areas of Bioko Island, Equatorial Guinea. Quantifying the impact of imported infections is difficult because of the dynamic nature of the disease and complexity of designing a randomized trial. We leverage a six-month travel moratorium in and out of Bioko Island during the initial COVID-19 pandemic response to evaluate the contribution of imported infections to malaria prevalence on Bioko Island. Using a difference in differences design and data from island wide household surveys conducted before (2019) and after (2020) the travel moratorium, we compare the change in prevalence between areas of low historical travel to those with high historical travel. Here, we report that in the absence of a travel moratorium, the prevalence of infection in high travel areas was expected to be 9% higher than observed, highlighting the importance of control measures that target imported infections.


Subject(s)
COVID-19 , Malaria, Falciparum , Plasmodium falciparum , SARS-CoV-2 , Travel , Humans , Equatorial Guinea/epidemiology , COVID-19/epidemiology , COVID-19/transmission , Prevalence , Malaria, Falciparum/epidemiology , SARS-CoV-2/isolation & purification , Pandemics , Female , Male , Islands , Adult , Betacoronavirus
4.
Parasites Hosts Dis ; 62(3): 302-312, 2024 Aug.
Article in English | MEDLINE | ID: mdl-39218629

ABSTRACT

Plasmodium falciparum apical membrane antigen-1 (PfAMA-1) is a major candidate for the blood-stage malaria vaccine. Genetic polymorphisms of global pfama-1suggest that the genetic diversity of the gene can disturb effective vaccine development targeting this antigen. This study was conducted to explore the genetic diversity and gene structure of pfama-1 among P. falciparum isolates collected in the Khyber Pakhtunkhwa (KP) province of Pakistan. A total of 19 full-length pfama-1 sequences were obtained from KP-Pakistan P. falciparum isolates, and genetic polymorphism and natural selection were investigated. KP-Pakistan pfama-1 exhibited genetic diversity, wherein 58 amino acid changes were identified, most of which were located in ectodomains, and domains I, II, and III. The amino acid changes commonly found in the ectodomain of global pfama-1 were also detected in KP-Pakistan pfama-1. Interestingly, 13 novel amino acid changes not reported in the global population were identified in KP-Pakistan pfama-1. KP-Pakistan pfama-1 shared similar levels of genetic diversity with global pfama-1. Evidence of natural selection and recombination events were also detected in KP-Pakistan pfama-1.


Subject(s)
Antigens, Protozoan , Malaria, Falciparum , Membrane Proteins , Plasmodium falciparum , Polymorphism, Genetic , Protozoan Proteins , Pakistan , Plasmodium falciparum/genetics , Antigens, Protozoan/genetics , Antigens, Protozoan/immunology , Antigens, Protozoan/chemistry , Protozoan Proteins/genetics , Protozoan Proteins/chemistry , Membrane Proteins/genetics , Humans , Malaria, Falciparum/parasitology , Malaria, Falciparum/epidemiology , Genetic Variation/genetics , Selection, Genetic , Phylogeny , Recombination, Genetic/genetics
5.
Int J Mol Sci ; 25(17)2024 Aug 26.
Article in English | MEDLINE | ID: mdl-39273187

ABSTRACT

The Plasmodium falciparum mitochondrial electron transport chain (mETC) is responsible for essential metabolic pathways such as de novo pyrimidine synthesis and ATP synthesis. The mETC complex III (cytochrome bc1 complex) is responsible for transferring electrons from ubiquinol to cytochrome c and generating a proton gradient across the inner mitochondrial membrane, which is necessary for the function of ATP synthase. Recent studies have revealed that the composition of Plasmodium falciparum complex III (PfCIII) is divergent from humans, highlighting its suitability as a target for specific inhibition. Indeed, PfCIII is the target of the clinically used anti-malarial atovaquone and of several inhibitors undergoing pre-clinical trials, yet its role in parasite biology has not been thoroughly studied. We provide evidence that the universally conserved subunit, PfRieske, and the new parasite subunit, PfC3AP2, are part of PfCIII, with the latter providing support for the prediction of its divergent composition. Using inducible depletion, we show that PfRieske, and therefore, PfCIII as a whole, is essential for asexual blood stage parasite survival, in line with previous observations. We further found that depletion of PfRieske results in gametocyte maturation defects. These phenotypes are linked to defects in mitochondrial functions upon PfRieske depletion, including increased sensitivity to mETC inhibitors in asexual stages and decreased cristae abundance alongside abnormal mitochondrial morphology in gametocytes. This is the first study that explores the direct role of the PfCIII in gametogenesis via genetic disruption, paving the way for a better understanding of the role of mETC in the complex life cycle of these important parasites and providing further support for the focus of antimalarial drug development on this pathway.


Subject(s)
Antimalarials , Atovaquone , Electron Transport Complex III , Malaria, Falciparum , Mitochondria , Plasmodium falciparum , Plasmodium falciparum/drug effects , Plasmodium falciparum/growth & development , Plasmodium falciparum/metabolism , Plasmodium falciparum/genetics , Atovaquone/pharmacology , Electron Transport Complex III/metabolism , Electron Transport Complex III/genetics , Electron Transport Complex III/antagonists & inhibitors , Antimalarials/pharmacology , Mitochondria/metabolism , Mitochondria/drug effects , Malaria, Falciparum/parasitology , Malaria, Falciparum/drug therapy , Humans , Protozoan Proteins/metabolism , Protozoan Proteins/genetics , Protozoan Proteins/antagonists & inhibitors , Life Cycle Stages/drug effects
6.
Int J Mol Sci ; 25(17)2024 Sep 05.
Article in English | MEDLINE | ID: mdl-39273566

ABSTRACT

Cerebral malaria in young African children is associated with high mortality, and persisting neurological deficits often remain in survivors. Sequestered Plasmodium-infected red blood cells lead to cerebrovascular inflammation and subsequent neuroinflammation. Brain inflammation can play a role in the pathogenesis of neurologic sequelae. Therefore, we assessed a select set of proinflammatory analytes (IP10, IL23, MIP3α, GRO, MCP-1, and osteopontin in both the plasma and cerebrospinal fluid(CSF) of Zambian children with cerebral malaria and compared this with children with neurological symptoms that were negative for Plasmodium falciparum (non-cerebral malaria). Several similarities in plasma and CSF levels were found, as were some striking differences. We confirmed that IP10 levels were higher in the plasma of cerebral malaria patients, but this was not found in CSF. Levels of osteopontin were elevated in both the plasma and CSF of CM patients compared to the non-CM patients. These results show again a highly inflammatory environment in both groups but a different profile for CM when compared to non-cerebral malaria. Osteopontin may play an important role in neurological inflammation in CM and the resulting sequelae. Therefore, osteopontin could be a valid target for further biomarker research and potentially for therapeutic interventions in neuroinflammatory infections.


Subject(s)
Biomarkers , Malaria, Cerebral , Osteopontin , Humans , Malaria, Cerebral/cerebrospinal fluid , Malaria, Cerebral/blood , Malaria, Cerebral/parasitology , Osteopontin/cerebrospinal fluid , Osteopontin/blood , Male , Female , Child, Preschool , Biomarkers/cerebrospinal fluid , Biomarkers/blood , Inflammation/cerebrospinal fluid , Inflammation/blood , Child , Plasmodium falciparum/pathogenicity , Infant , Malaria, Falciparum/cerebrospinal fluid , Malaria, Falciparum/blood , Malaria, Falciparum/parasitology
7.
BMC Infect Dis ; 24(1): 1028, 2024 Sep 26.
Article in English | MEDLINE | ID: mdl-39327613

ABSTRACT

BACKGROUND: The World Health Organization 2022 malaria chemoprevention guidelines recommend providing a full course of antimalarial treatment at pre-defined intervals, regardless of malaria status to prevent illness among children resident in moderate to high perennial malaria transmission settings as perennial malaria chemoprevention (PMC) with sulfadoxine-pyrimethamine (SP). The dhps I431V mutation circulating in West Africa has unknown effect on SP protective efficacy. METHODS: This protocol is for a three-arm, parallel, double-blinded, placebo-controlled, randomised trial in Cameroon among children randomly assigned to one of three directly-observed treatment groups: (i) Group 1 (n = 450) receives daily artesunate (AS) placebo on days - 7 to -1, then active SP plus placebo amodiaquine (AQ) on day 0, and placebo AQ on days 1 and 2; (ii) Group 2 (n = 250) receives placebo AS on days - 7 to -1, then active SP and AQ on day 0, and active AQ on days 1 and 2; and (iii) Group 3 (n = 200) receives active AS on days - 7 to -1, then placebo SP on day 0 and placebo AQ on days 0 to 2. On days 0, 2, 5, 7, and thereafter weekly until day 28, children provide blood for thick smear slides. Dried blood spots are collected on the same days and weekly from day 28 to day 63 for quantitative polymerase chain reaction (qPCR) and genotype analyses. DISCUSSION: Our aim is to quantify the chemopreventive efficacy of SP, and SP plus AQ, and measure the effect of the parasite genotypes associated with SP resistance on parasite clearance and protection from infection when exposed to SP chemoprevention. We will report unblinded results including: (i) time-to-parasite clearance among SP and SP plus AQ recipients who were positive on day 0 by qPCR and followed to day 63; (ii) mean duration of SP and SP plus AQ protection against infection, and (iii) mean duration of symptom-free status among SP and SP plus AQ recipients who were parasite free on day 0 by qPCR. Our study is designed to compare the 28-day follow-up of the new WHO malaria chemoprevention efficacy study protocol with extended follow-up to day 63. TRIAL REGISTRATION: ClinicalTrials.gov NCT06173206; 15/12/2023.


Subject(s)
Amodiaquine , Antimalarials , Artesunate , Drug Combinations , Malaria, Falciparum , Plasmodium falciparum , Pyrimethamine , Sulfadoxine , Humans , Pyrimethamine/therapeutic use , Pyrimethamine/administration & dosage , Cameroon , Sulfadoxine/therapeutic use , Sulfadoxine/administration & dosage , Malaria, Falciparum/prevention & control , Malaria, Falciparum/drug therapy , Malaria, Falciparum/parasitology , Antimalarials/therapeutic use , Antimalarials/administration & dosage , Child, Preschool , Amodiaquine/therapeutic use , Plasmodium falciparum/drug effects , Plasmodium falciparum/genetics , Double-Blind Method , Female , Male , Artesunate/therapeutic use , Artemisinins/therapeutic use , Artemisinins/administration & dosage , Treatment Outcome , Chemoprevention/methods
8.
PLoS Pathog ; 20(9): e1012484, 2024 Sep.
Article in English | MEDLINE | ID: mdl-39241090

ABSTRACT

Glycophosphatidylinositol (GPI) anchors are the predominant glycoconjugate in Plasmodium parasites, enabling modified proteins to associate with biological membranes. GPI biosynthesis commences with donation of a mannose residue held by dolichol-phosphate at the endoplasmic reticulum membrane. In Plasmodium dolichols are derived from isoprenoid precursors synthesised in the Plasmodium apicoplast, a relict plastid organelle of prokaryotic origin. We found that treatment of Plasmodium parasites with apicoplast inhibitors decreases the synthesis of isoprenoid and GPI intermediates resulting in GPI-anchored proteins becoming untethered from their normal membrane association. Even when other isoprenoids were chemically rescued, GPI depletion led to an arrest in schizont stage parasites, which had defects in segmentation and egress. In those daughter parasites (merozoites) that did form, proteins that would normally be GPI-anchored were mislocalised, and when these merozoites were artificially released they were able to attach to but not invade new red blood cells. Our data provides further evidence for the importance of GPI biosynthesis during the asexual cycle of P. falciparum, and indicates that GPI biosynthesis, and by extension egress and invasion, is dependent on isoprenoids synthesised in the apicoplast.


Subject(s)
Apicoplasts , Glycosylphosphatidylinositols , Plasmodium falciparum , Terpenes , Plasmodium falciparum/metabolism , Apicoplasts/metabolism , Glycosylphosphatidylinositols/metabolism , Glycosylphosphatidylinositols/biosynthesis , Terpenes/metabolism , Protozoan Proteins/metabolism , Protozoan Proteins/genetics , Erythrocytes/parasitology , Erythrocytes/metabolism , Humans , Malaria, Falciparum/parasitology , Malaria, Falciparum/metabolism , Animals , Merozoites/metabolism
9.
MSMR ; 31(8): 14-19, 2024 08 20.
Article in English | MEDLINE | ID: mdl-39255515

ABSTRACT

Australian Defence Force (ADF) personnel train and operate in malarious regions that include neighboring countries with high burden and species with latent hepatic parasites.1 We summarized longitudinal malaria case data, following a prior 10-year period review to 2007.2 Malaria case entries within the ADF Malaria and Infectious Diseases Institute (ADFMIDI)-managed Central Malaria Register (CMR) were examined. Data from cases confirmed between January 1, 2008 through December 31, 2022 were analyzed. Sixty ADF members were diagnosed with malaria, including 1 with a mixed Plasmodium falciparum and P. vivax infection. Of 61 malaria infections, 69% (42 of 61) were P. vivax. P. vivax infection resulted in delayed initial case presentation (more than 4 weeks after exposure) in at least 36% (15 of 42) of cases, and 5 personnel experienced further relapse. Most P. vivax infections were acquired in the U.S. Indo-Pacific Command (INDOPACOM) and P. falciparum in the U.S. Africa Command (AFRICOM) regions. The ADF experienced ongoing reduced malaria case incidence following high rates in the early 2000s. Maintenance of prophylactic vigilance, both for eradicating dormant hypnozoites and preventing P. vivax relapse, remains important, however.


Subject(s)
Malaria, Falciparum , Malaria, Vivax , Military Personnel , Humans , Military Personnel/statistics & numerical data , Australia/epidemiology , Male , Female , Adult , Malaria, Vivax/epidemiology , Malaria, Falciparum/epidemiology , Young Adult , Incidence , Middle Aged , Plasmodium vivax/isolation & purification , Malaria/epidemiology , Plasmodium falciparum/isolation & purification , Registries
10.
Parasit Vectors ; 17(1): 401, 2024 Sep 20.
Article in English | MEDLINE | ID: mdl-39304934

ABSTRACT

BACKGROUND: Malaria is a mosquito-transmitted disease that kills more than half a million people annually. The lack of effective malaria vaccines and recently increasing malaria cases urge innovative approaches to prevent malaria. Previously, we reported that the extract from the soil-dwelling fungus Purpureocillium lilacinum, a common fungus from the soil, reduced Plasmodium falciparum oocysts in Anopheles gambiae midguts after mosquitoes contacted the treated surface before feeding. METHODS: We used liquid chromatography to fraction fungal crude extract and tract the active fraction using a contact-wise approach and standard membrane feeding assays. The purified small molecules were analyzed using precise mass spectrometry and tandem mass spectrometry. RESULTS: We isolated four active small molecules from P. lilacinum and determined them as leucinostatin A, B, A2, and B2. Pre-exposure of mosquitoes via contact with very low-concentration leucinostatin A significantly reduced the number of oocysts. The half-maximal response or inhibition concentration (EC50) via pre-exposure was 0.7 mg/m2, similar to atovaquone but lower than other known antimalarials. The inhibitory effect of leucinostatin A against P. falciparum during intraerythrocytic development, gametogenesis, sporogonic development, and ookinete formation, with the exception of oocyst development, suggests that leucinostatins play a part during parasite invasion of new cells. CONCLUSIONS: Leucinostatins, secondary metabolites from P. lilacinum disrupt malaria development, particular transmission to mosquitoes by contact. The contact-wise malaria control as a nonconventional approach is highly needed in malaria-endemic areas.


Subject(s)
Anopheles , Plasmodium falciparum , Animals , Anopheles/drug effects , Anopheles/parasitology , Anopheles/microbiology , Plasmodium falciparum/drug effects , Mosquito Vectors/drug effects , Mosquito Vectors/parasitology , Mosquito Vectors/microbiology , Hypocreales/chemistry , Hypocreales/drug effects , Antimalarials/pharmacology , Antimalarials/chemistry , Oocysts/drug effects , Malaria, Falciparum/transmission , Malaria, Falciparum/prevention & control , Malaria, Falciparum/parasitology , Chromatography, Liquid , Female , Antimicrobial Cationic Peptides
11.
PLoS Pathog ; 20(9): e1012514, 2024 Sep.
Article in English | MEDLINE | ID: mdl-39298535

ABSTRACT

Plasmodium falciparum undergoes sequestration within deep tissues of the human body, spanning multiple organ systems with differing oxygen (O2) concentrations. The parasite is exposed to an even greater range of O2 concentrations as it transitions from the human to the mosquito host, suggesting a high level of plasticity as it navigates these different environments. In this review, we explore factors that may contribute to the parasite's response to different environmental O2 concentrations, recognizing that there are likely multiple pieces to this puzzle. We first review O2-sensing mechanisms, which exist in other apicomplexans such as Toxoplasma gondii and consider whether similar systems could exist in Plasmodium. Next, we review morphological and functional changes in P. falciparum's mitochondrion during the asexual-to-sexual stage transition and discuss how these changes overlap with the parasite's access to O2. We then delve into reactive oxygen species (ROS) as ROS production is influenced by O2 availability and oxidative stress impacts Plasmodium intraerythrocytic development. Lastly, given that the primary role of the red blood cell (RBC) is to deliver O2 throughout the body, we discuss how changes in the oxygenation status of hemoglobin, the RBC's O2-carrying protein and key nutrient for Plasmodium, could also potentially impact the parasite's growth during intraerythrocytic development. This review also highlights studies that have investigated P. falciparum biology under varying O2 concentrations and covers technical aspects related to P. falciparum cultivation in the lab, focusing on sources of technical variation that could alter the amount of dissolved O2 encountered by cells during in vitro experiments. Lastly, we discuss how culture systems can better replicate in vivo heterogeneity with respect to O2 gradients, propose ideas for further research in this area, and consider translational implications related to O2 and malaria.


Subject(s)
Erythrocytes , Malaria, Falciparum , Oxygen , Plasmodium falciparum , Plasmodium falciparum/metabolism , Plasmodium falciparum/physiology , Humans , Oxygen/metabolism , Malaria, Falciparum/parasitology , Malaria, Falciparum/metabolism , Erythrocytes/parasitology , Erythrocytes/metabolism , Animals , Reactive Oxygen Species/metabolism , Life Cycle Stages/physiology , Oxidative Stress
12.
Malar J ; 23(1): 282, 2024 Sep 17.
Article in English | MEDLINE | ID: mdl-39289715

ABSTRACT

BACKGROUND: Artemether-lumefantrine (AL) has been the primary anti-malarial drug used to treat uncomplicated Plasmodium falciparum malaria in Ethiopia since 2004. However, there have been recent reports of AL resistance mutations in different African countries, including Ethiopia. This is concerning and requires periodic monitoring of anti-malarial drug resistance. Therefore, the current study aimed to evaluate the therapeutic efficacy of AL in treating uncomplicated P. falciparum malaria in the Arba Minch Zuria District, Gamo Zone, Southwest Ethiopia. METHODS: A single-arm prospective study with a 28-day follow-up period was conducted from July to October 2022. Capillary blood samples were collected for RDT and microscopic examination. The study enrolled monoinfected P. falciparum patients aged ≥ 18 years at Ganta Sira Health Post. Sociodemographic and clinical data were recorded, and a dried blood spot (DBS) was prepared for each participant. Nested polymerase chain reaction (nPCR) genotyping of the msp-1 and msp-2 genes was only performed for recurrent cases to distinguish between recurrence and reinfection. Data entry and analysis were performed using the WHO Excel spreadsheet and SPSS version 26. RESULTS: A total of 89 patients were enrolled, and 67 adequately completed the 28-day follow-up period. AL showed a 100% clearance rate for fever on day 2 and asexual parasites on day 3. Gametocytes were detected in 13.5% (12/89) of the participants. The gametocyte clearance rate was 58.3% (7/12) until day 7 and 100% (12/12) until day 14. Five participants developed recurrent malaria, three of whom experienced relapse and two of whom experienced reinfection. Based on the Kaplan-Meier survival analysis, the PCR-uncorrected and PCR-corrected cumulative incidence of success were 93.7% (95% CI 85.5-97.3) and 96.2% (95% CI 85.5-98.7), respectively. CONCLUSION: AL was efficacious in treating uncomplicated P. falciparum malaria in the study area. However, the detection of recurrent patients highlights the need for continuous efficacy studies in this area.


Subject(s)
Antimalarials , Artemether, Lumefantrine Drug Combination , Malaria, Falciparum , Plasmodium falciparum , Artemether, Lumefantrine Drug Combination/therapeutic use , Ethiopia , Malaria, Falciparum/drug therapy , Malaria, Falciparum/parasitology , Humans , Male , Antimalarials/therapeutic use , Female , Adult , Young Adult , Adolescent , Prospective Studies , Middle Aged , Plasmodium falciparum/drug effects , Plasmodium falciparum/genetics , Aged , Merozoite Surface Protein 1/genetics , Antigens, Protozoan/genetics , Protozoan Proteins/genetics
13.
Immun Inflamm Dis ; 12(9): e70013, 2024 Sep.
Article in English | MEDLINE | ID: mdl-39240033

ABSTRACT

BACKGROUND: Severe Plasmodium falciparum malarial anemia is still the principal cause of death in children in underdeveloped countries. An imbalance between proinflammatory and anti-inflammatory cytokines is associated with malaria progression. This study evaluated circulating levels of selected inflammatory cytokines among malaria-infected children in Ghana. METHODS: This case-control study was conducted at Tamale Teaching Hospital, Ghana. One hundred and twenty children with malaria and 60 controls, aged 12-144 months were selected from April to July, 2023 for the study. Malaria was diagnosed through microscopy, full blood count was measured using hematology analyzer, and cytokines were measured using enzyme-linked immunosorbent assay. RESULTS: Malaria-infected children had higher tumor necrosis factor alpha (TNF-α) (p < .001), interferon-gamma (IFN-É£) (p < .001), interleukin (IL)-1ß (p < .001), IL-6 (p < .001), granulocyte macrophage-colony stimulating factor (GM-CSF) (p < .001), and IL-10 (p < .001) levels than controls. Participants with high parasitemia had raised TNF-α (p < .001), IFN-É£ (p < .001), IL-1ß (p < .001), IL-6 (p < .001), GM-CSF (p < .001), and IL-10 (p < .001), but reduced IL-3 (p < .001) and TGF-ß (p < .001) than those with low parasitemia. Severe malarial anemic children had elevated TNF-α (p < .001), IFN-É£ (p < .001), IL-1ß (p < .001), IL-6 (p < .001), GM-CSF (p < .001), and IL-10 (p < .001), but lower IL-3 (p < .001) and TGF-ß (p < .001) than those with uncomplicated malaria. CONCLUSION: Parasite density was the principal predictor of the cytokine levels, as parasitemia positively associated with IL-10, GM-CSF, IL-6, IL-1ß, IFN-É£, and TNF-α, but negatively associated with IL-3 and TGF-ß. Malaria is associated with enhanced secretion of pro- and anti-inflammatory cytokines in Ghanaian children. Inflammatory cytokines may be involved in the development of severe malarial anemia in children. However, IL-3 and TGF-ß may offer protection against severe malarial anemia.


Subject(s)
Anemia , Cytokines , Disease Progression , Malaria, Falciparum , Humans , Cytokines/blood , Anemia/blood , Anemia/immunology , Anemia/parasitology , Male , Child, Preschool , Female , Prospective Studies , Case-Control Studies , Infant , Malaria, Falciparum/blood , Malaria, Falciparum/immunology , Malaria, Falciparum/complications , Malaria, Falciparum/parasitology , Malaria, Falciparum/epidemiology , Ghana/epidemiology , Child , Parasitemia/blood , Parasitemia/immunology , Plasmodium falciparum/immunology , Inflammation Mediators/blood
14.
Malar J ; 23(1): 272, 2024 Sep 10.
Article in English | MEDLINE | ID: mdl-39256754

ABSTRACT

BACKGROUND: Reactive case detection (RCD) aims to reduce malaria transmission stemming from asymptomatic carriers. Symptomatic individuals diagnosed with malaria at a health centre are followed to their households, where members of the index case and neighbouring households are tested and treated for malaria. An RCD programme was tested in the Ashanti region of Ghana in order to study diagnostic accuracy in the hospital and household settings, assess the prevalence of subclinical infections and possible clustering in index case households, and identify operational challenges for future RCD programmes. Currently, transmission in this region is high, but reactive interventions might become an option once transmission is reduced. METHODS: 264 febrile individuals were enrolled at the Mankranso Government Hospital and tested for malaria using rapid diagnostic tests (RDT). From the pool of RDT-positive febrile index cases, 14 successful RCD follow-ups were conducted, and 233 individuals were enrolled from the index case, neighbour, and control households. The sensitivity of diagnostic tools for clinical and subclinical cases was compared, including RDT, expert microscopy by World Health Organization-certified microscopists, field microscopy, and qPCR. RESULTS: Poor diagnosis and low receptivity to RCD-style follow-ups were major limitations to a successful and effective RCD programme. Field microscopy detected only 49% of clinical infections compared to RDT. 54% of individuals did not agree to a follow-up, and 66% of attempted follow-ups failed. The system effectiveness of RCD, calculated as the product of correctly diagnosed index cases, successful follow-ups, and proportion of asymptomatic infections detected by RDT, was very low at 4.0%. CONCLUSIONS: Due to low system effectiveness and the endemic nature of the disease setting in which asymptomatic prevalence is high and infections are not clustered around index case households, RCD is currently not a feasible option for malaria control in this region. The operational challenges identified through this study may help inform future reactive intervention programme designs once transmission is reduced.


Subject(s)
Asymptomatic Infections , Diagnostic Tests, Routine , Malaria, Falciparum , Ghana/epidemiology , Humans , Malaria, Falciparum/diagnosis , Malaria, Falciparum/epidemiology , Malaria, Falciparum/prevention & control , Asymptomatic Infections/epidemiology , Female , Male , Child, Preschool , Child , Adolescent , Diagnostic Tests, Routine/methods , Diagnostic Tests, Routine/statistics & numerical data , Adult , Young Adult , Infant , Middle Aged , Plasmodium falciparum/isolation & purification , Prevalence , Sensitivity and Specificity , Aged
15.
Malar J ; 23(1): 275, 2024 Sep 10.
Article in English | MEDLINE | ID: mdl-39256807

ABSTRACT

BACKGROUND: Human serum is a major component of Plasmodium falciparum culture medium, and can be replaced with AlbuMAX™ II, a lipid-rich bovine serum albumin, for asexual cultures. However, gametocytes produced without serum are poorly infective to mosquitoes. Serum suffers from high cost, limited availability, and variability in quality. METHODS: Several commercially-available media supplements were tested for their ability to support parasite growth and production of P. falciparum (3D7) gametocytes in standard RPMI1640 medium containing 0.5% AlbuMAX. The impact on asexual growth and gametocyte production with each supplement was assessed and compared to standard RPMI1640 medium containing 10% human serum, as well as to medium containing 0.5% AlbuMAX alone. The infectivity of gametocytes produced with one supplement to Anopheles gambiae sensu stricto was assessed by standard membrane feeding assay and measuring both prevalence of infection and oocyst intensity. RESULTS: Supplementation of medium containing 0.5% AlbuMAX with five supplements did not affect asexual growth of P. falciparum, and four of the five supplements supported early gametocyte production. The supplement producing the highest number of gametocytes, ITS-X, was further investigated and was found to support the production of mature gametocytes. Infection prevalence and oocyst intensity did not differ significantly between mosquitoes given a membrane feed containing gametocytes grown in medium with 0.5% AlbuMAX + ITS-X and those grown in medium with 10% human serum. Infection prevalence and oocyst intensity was significantly higher in case of ITS-X supplementation when compared to AlbuMAX alone. Infectious gametocytes were also produced from two field clones using ITS-X supplementation. CONCLUSIONS: Serum-free medium supplemented with ITS-X was able to support the growth of gametocytes of P. falciparum that were as infectious to An. gambiae as those grown in medium with 10% serum. This is the first fully serum-free culture system able to produce highly infectious gametocytes, thereby removing the requirement for access to serum for transmission assays.


Subject(s)
Anopheles , Plasmodium falciparum , Plasmodium falciparum/physiology , Plasmodium falciparum/drug effects , Plasmodium falciparum/growth & development , Animals , Anopheles/parasitology , Culture Media, Serum-Free , Humans , Malaria, Falciparum/parasitology , Malaria, Falciparum/prevention & control
16.
Malar J ; 23(1): 268, 2024 Sep 04.
Article in English | MEDLINE | ID: mdl-39232787

ABSTRACT

BACKGROUND: Asymptomatic carriage of infected red blood cells (iRBCs) can be prevalent in communities regardless of transmission patterns and can occur with infection of different Plasmodium species. Clinical immunity dampens the inflammatory responses leading to disease symptoms in malaria. The aim of this study was to define the immunological correlates of asymptomatic carriage of Plasmodium falciparum in a highly exposed population. METHODS: 142 asymptomatic Plasmodium-infected individuals greater than 2 years of age without fever (body temperature <37.5 ℃) were followed weekly for 10 weeks before being treated with artemisinin-based combination therapy (ACT). Plasma levels of 38 cytokines were measured at baseline by Luminex and the quantity and growth inhibitory activities of circulating parasite-reactive antibodies measured. The Plasmodium antigen tested included P. falciparum merozoite extract (ME) and schizont extract (SE), and the recombinant proteins erythrocyte binding antigen 175 (EBA-175) and merozoite surface protein 1 (MSP-119). RESULTS: Median levels of IgG against P. falciparum EBA-175 and MSP-119 at baseline were significantly higher in those older than 20 years of age compared with the younger age group and appeared to correlate with better parasite control. Amongst all participants there were no discernible changes in IgG levels over time. Parasite density was higher in the younger age group and associated with IL-10, TNF and MCP-1 levels. A balanced IL-10:TNF ratio was associated with asymptomatic malaria regardless of age, and balanced ratios of IL-10/TNF and IL-10/IFN-γ were the only significant correlate of maintenance of asymptomatic malaria over the course of the study in individuals 20 years of age and younger. CONCLUSION: The above findings indicate that asymptomatic carriage of P. falciparum in children living in a hyperendemic area occurs independently of IgG but is associated with a balanced inflammatory cytokine ratio.


Subject(s)
Carrier State , Cytokines , Immunoglobulin G , Malaria, Falciparum , Plasmodium falciparum , Humans , Plasmodium falciparum/immunology , Plasmodium falciparum/physiology , Child , Immunoglobulin G/blood , Child, Preschool , Malaria, Falciparum/epidemiology , Malaria, Falciparum/immunology , Malaria, Falciparum/parasitology , Cytokines/blood , Adolescent , Male , Female , Carrier State/epidemiology , Young Adult , Asymptomatic Infections/epidemiology , Antibodies, Protozoan/blood , Endemic Diseases/statistics & numerical data
17.
Parasitol Res ; 123(9): 311, 2024 Aug 30.
Article in English | MEDLINE | ID: mdl-39222092

ABSTRACT

Striking morphological transformations characterize the invasion of a red blood cell by the malaria parasite. Shortly after the infection, parasite-induced membranes appear in the cytosol of the affected host erythrocyte. One intensely investigated membrane type, commonly called Maurer's clefts, has a slit-like morphology and can be arranged in the form of extended three-dimensional membrane stacks or networks. Here we report the three-dimensional reconstruction of a second membrane type, giant or extended membrane rings/loops, that have only occasionally been described on single ultrathin sections, however that have never been systematically examined so far. Serial ultrathin sectioning of P. falciparum-infected red blood cells, subsequent three-dimensional reconstructions, and in addition examination of Giemsa-stained blood films revealed that intraerythrocytic membrane rings/loops are not isolated structures but are locally in contact with the parasite. They consist either of the parasitophorous vacuolar membrane alone or contain the parasitophorous vacuolar membrane including the plasma membrane of the parasite and small amounts of parasite cytoplasm. We demonstrate that membrane rings/loops represent surface extensions of the parasite that maybe involved in ring stage parasite formation and Maurer's cleft generation at least in a subset of infected red blood cells.


Subject(s)
Cytosol , Erythrocytes , Plasmodium falciparum , Erythrocytes/parasitology , Plasmodium falciparum/physiology , Cytosol/parasitology , Cytosol/chemistry , Humans , Erythrocyte Membrane/parasitology , Erythrocyte Membrane/ultrastructure , Malaria, Falciparum/parasitology , Imaging, Three-Dimensional , Cell Membrane/parasitology
18.
Nat Commun ; 15(1): 7659, 2024 Sep 03.
Article in English | MEDLINE | ID: mdl-39227370

ABSTRACT

The selection and combination of dose regimens for antimalarials involve complex considerations including pharmacokinetic and pharmacodynamic interactions. In this study, we use immediate ex vivo P. falciparum field isolates to evaluate the effect of cabamiquine and pyronaridine as standalone treatments and in combination therapy. We feed the data into a pharmacometrics model to generate an interaction map and simulate meaningful clinical dose ratios. We demonstrate that the pharmacometrics model of parasite growth and killing provides a detailed description of parasite kinetics against cabamiquine-susceptible and resistant parasites. Pyronaridine monotherapy provides suboptimal killing rates at doses as high as 720 mg. In contrast, the combination of a single dose of 330 mg cabamiquine and 360 mg pyronaridine provides over 90% parasite killing in most of the simulated patients. The described methodology that combines a rapid, 3R-compliant in vitro method and modelling to set meaningful doses for new antimalarials could contribute to clinical drug development.


Subject(s)
Antimalarials , Malaria, Falciparum , Naphthyridines , Plasmodium falciparum , Plasmodium falciparum/drug effects , Antimalarials/pharmacology , Antimalarials/administration & dosage , Antimalarials/pharmacokinetics , Humans , Malaria, Falciparum/drug therapy , Malaria, Falciparum/parasitology , Naphthyridines/administration & dosage , Naphthyridines/pharmacology , Naphthyridines/pharmacokinetics , Drug Therapy, Combination , Dose-Response Relationship, Drug , Drug Resistance/drug effects
19.
PLoS One ; 19(9): e0309058, 2024.
Article in English | MEDLINE | ID: mdl-39226299

ABSTRACT

BACKGROUND: Endemic African malaria vectors are poorly adapted to typical urban ecologies. However, Anopheles stephensi, an urban malaria vector formerly confined to South Asia and the Persian Gulf, was recently detected in Africa and may change the epidemiology of malaria across the continent. Little is known about the public health implications of An. stephensi in Africa. This study is designed to assess the relative importance of household exposure to An. stephensi and endemic malaria vectors for malaria risk in urban Sudan and Ethiopia. METHODS: Case-control studies will be conducted in 3 urban settings (2 in Sudan, 1 in Ethiopia) to assess the association between presence of An. stephensi in and around households and malaria. Cases, defined as individuals positive for Plasmodium falciparum and/or P. vivax by microscopy/rapid diagnostic test (RDT), and controls, defined as age-matched individuals negative for P. falciparum and/or P. vivax by microscopy/RDT, will be recruited from public health facilities. Both household surveys and entomological surveillance for adult and immature mosquitoes will be conducted at participant homes within 48 hours of enrolment. Adult and immature mosquitoes will be identified by polymerase chain reaction (PCR). Conditional logistic regression will be used to estimate the association between presence of An. stephensi and malaria status, adjusted for co-occurrence of other malaria vectors and participant gender. CONCLUSIONS: Findings from this study will provide evidence of the relative importance of An. stephensi for malaria burden in urban African settings, shedding light on the need for future intervention planning and policy development.


Subject(s)
Anopheles , Mosquito Vectors , Anopheles/parasitology , Ethiopia/epidemiology , Sudan/epidemiology , Animals , Humans , Case-Control Studies , Mosquito Vectors/parasitology , Family Characteristics , Malaria/epidemiology , Malaria/transmission , Malaria, Falciparum/epidemiology , Malaria, Falciparum/transmission , Plasmodium falciparum/isolation & purification , Female , Male
20.
Trials ; 25(1): 583, 2024 Sep 03.
Article in English | MEDLINE | ID: mdl-39227956

ABSTRACT

BACKGROUND: Primaquine (PQ) has activity against mature P. falciparum gametocytes and proven transmission blocking efficacy (TBE) between humans and mosquitoes. WHO formerly recommended a single transmission blocking dose of 0.75 mg/kg but this was little used. Then in 2012, faced with the emergence of artemisinin-resistant P. falciparum (ARPf) in SE Asia, the WHO recommended a lower dose of 0.25 mg/kg to be added to artemisinin-based combination therapy in falciparum-infected patients in low transmission areas. This dose was considered safe in glucose-6-phosphate dehydrogenase deficiency (G6PDd) and not requiring G6PD testing. Subsequent single low-dose primaquine (SLDPQ) studies have demonstrated safety in different G6PD variants. Dosing remains challenging in children under the age of 5 because of the paucity of PQ pharmacokinetic (PK) data. We plan to assess the anti-infectivity efficacy of SLDPQ using an allometrically scaled, weight-based regimen, with a target dose of 0.25 mg/kg, in children with acute uncomplicated falciparum malaria. METHODS: This study is an open label, randomised 1:1, phase IIb study to assess TBE, tolerability, pharmacokinetics and acceptability of artesunate pyronaridine (ASPYR) administered alone or combined with SLDPQ in 56 Burkinabe children aged ≥ 6 months- < 5 years, with uncomplicated P. falciparum and a haemoglobin (Hb) concentration of ≥ 5 g/dL. We will assess TBE, using direct membrane feeding assays (DMFA), and further investigate PQ pharmacokinetics, adverse events, Hb dynamics, G6PD, sickle cells, thalassaemia and cytochrome 2D6 (CYP2D6) status, acceptability of flavoured PQ [CAST-ClinSearch Acceptability Score Test®], and the population's knowledge, attitude and practices on malaria. EXPECTED RESULTS AND DISCUSSION: We expect children to accept tablets, confirm the TBE and gametocytocidal effects of SLDPQ and then construct a PK infectivity model (including age, sex, baseline Hb, G6PD and CYP2D6 status) to define the dose response TBE relationship that may lead to fine tuning our SLDPQ regimen. Our study will complement others that have examined factors associated with Hb dynamics and PQ PK. It will provide much needed, high-quality evidence of SLDPQ in sick African children and provide reassurance that SLDPQ should be used as a strategy against emerging ARPf in Africa. TRIAL REGISTRATION: ISRCTN16297951. Registered on September 26, 2021.


Subject(s)
Antimalarials , Malaria, Falciparum , Plasmodium falciparum , Primaquine , Randomized Controlled Trials as Topic , Humans , Malaria, Falciparum/drug therapy , Malaria, Falciparum/parasitology , Primaquine/pharmacokinetics , Primaquine/administration & dosage , Primaquine/adverse effects , Burkina Faso , Antimalarials/pharmacokinetics , Antimalarials/administration & dosage , Antimalarials/adverse effects , Child, Preschool , Plasmodium falciparum/drug effects , Male , Treatment Outcome , Female , Infant , Clinical Trials, Phase II as Topic , Artemisinins/pharmacokinetics , Artemisinins/administration & dosage , Artemisinins/adverse effects , Artemisinins/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL